Monitor for any subsequent filings that may indicate further executive changes or financial reporting delays, though the internal promotion of the CFO to principal accounting officer suggests operational continuity.
TCRX drugs
TCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 2 $1.01entry
- T+1 · 8mo ago +2.97%α +2.49% · $1.04
- T+5 · 7mo ago +3.96%α +0.34% · $1.05
- T+20 · 7mo ago +14.85%α +4.97% · $1.16
- T+60 · 5mo ago −2.96%α −17.12% · $0.9801
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics announced the resignation of Leiden Dworak as Vice President of Finance and principal accounting officer, effective April 10, 2026. Jason A. Amello, the company's CFO, has been appointed as the new principal accounting officer without additional compensation.
Key Facts
- Leiden Dworak resigned as Vice President of Finance and principal accounting officer effective April 10, 2026.
- Jason A. Amello, current CFO and principal financial officer, was appointed as principal accounting officer effective April 10, 2026.
- No disagreements were reported between the company and Mr. Dworak regarding operations, policies, or practices.
- Mr. Amello will not receive additional compensation for taking on the expanded role.
Financial Impact
No immediate financial impact; no change in compensation or organizational costs.
Risk Factors
- Potential transitional risk in financial oversight during the role transfer, though mitigated by Amello's existing CFO position.
- Limited insight into Dworak's reasons for departure beyond 'resignation,' though no reported disagreements reduce immediate concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-138973 |
| Document: 0001193125-26-138973-index-headers.html | 0001193125-26-138973 |
| Document: 0001193125-26-138973-index.html | 0001193125-26-138973 |
| Document: 0001193125-26-138973.txt | 0001193125-26-138973 |
Track record
15 reports on TCRX
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers